Differences in significance of drug resistance mechanisms between adult and childhood acute lymphoblastic leukemia

被引:0
|
作者
Styczynski, J [1 ]
Wysocki, M [1 ]
机构
[1] Med Univ, Dept Pediat Hematol & Oncol, PL-85094 Bydgoszcz, Poland
关键词
acute lymphoblastic leukemia; drug resistance;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute lymphoblastic leukemia (ALL) is now curable in 60-80% of children. In adults, in spite of adopting treatment protocols based on therapy for childhood ALL, the disease is still curable in 30-40% of patients only. These worse results of therapy may be due to the induction of various cell defence mechanisms, such as activation of P-glycoprotein, which protects man against xenobiotics. Among a number of various multi-drug resistance mechanisms, differences between adults and children with ALL have been found only for higher P-glycoprotein expression and possibly more often p53 gene mutations in adults. Induction of expression of drug resistance proteins during chemotherapy and co-existence of various mechanisms are common phenomena in adult ALL. Differences in resistance to different drugs might contribute to the impact of age on the outcome of ALL. The underlying mechanisms for these differences are still largely unknown; however, knowledge about drug resistance mechanisms can lead to new therapeutic options.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 50 条
  • [21] Displacement of Coilin in Cajal Body Is Related to Drug Resistance of Childhood Acute Lymphoblastic Leukemia
    Yue, Zhixia
    Song, Yaoyao
    Niu, Jing
    Liu, Shuguang
    Ding, Wei
    BLOOD, 2016, 128 (22)
  • [22] Cellular drug resistance is associated with alterations in the apoptotic pathway in childhood acute lymphoblastic leukemia
    den Boer, ML
    Holleman, A
    Kazemier, KM
    Janka-Schaub, GE
    Pieters, R
    BLOOD, 2002, 100 (11) : 222B - 222B
  • [23] Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia?
    Styczynski, J
    Wysocki, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 963 - 964
  • [24] Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia
    Pogorzala, Monika
    Kubicka, Malgorzata
    Rafinska, Beata
    Wysocki, Mariusz
    Styczynski, Jan
    ANTICANCER RESEARCH, 2015, 35 (10) : 5667 - 5670
  • [25] Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia
    Matherly, LH
    Taub, JW
    LEUKEMIA & LYMPHOMA, 1996, 21 (5-6) : 359 - 368
  • [26] Drug resistance mechanisms in acute leukemia
    Chauncey, TR
    CURRENT OPINION IN ONCOLOGY, 2001, 13 (01) : 21 - 26
  • [27] CLINICAL SIGNIFICANCE OF CYTOCHEMICAL FINDINGS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
    WINKLER, K
    STUHRK, H
    GAEDICKE, G
    MARSMANN, G
    LANDBECK, G
    KLINISCHE PADIATRIE, 1977, 189 (01): : 22 - 30
  • [28] SIGNIFICANCE OF SPLENOMEGALY IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA IN REMISSION
    MANOHARAN, A
    CATOVSKY, D
    GOLDMAN, JM
    LAURIA, F
    LAMPERT, IA
    GALTON, DAG
    LANCET, 1980, 1 (8166): : 449 - 452
  • [29] PROGNOSTIC SIGNIFICANCE OF GLUCOCORTICOID RECEPTORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
    MASTRANGELO, R
    RICCARDI, R
    MALANDRINO, R
    RANELLETTI, FO
    LONGO, P
    IACOBELLI, S
    CANCER TREATMENT REPORTS, 1979, 63 (07): : 1165 - 1165
  • [30] EXPRESSION AND PROGNOSTIC-SIGNIFICANCE OF RESISTANCE PROTEINS IN INITIAL CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    SAUERBREY, A
    VOLM, M
    ZINTL, F
    KLINISCHE PADIATRIE, 1995, 207 (04): : 230 - 234